The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability

Oncogene

Volumn 32, Issue 43, 2013, Pages 5167-5175

  Yang, W C ^a,b,c   Shih, H M ^a,b,c  

^a ACADEMIA SINICA   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

acute promyelocytic leukemia; deubiquitinating enzyme; PLZF; RARA; USP37

Indexed keywords

ARSENIC TRIOXIDE; ONCOPROTEIN; PLZF RARA FUSION PROTEIN; PROTEASOME; PROTEIN USP37; RETINOIC ACID; UBIQUITIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE REPRESSION; HALF LIFE TIME; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; NONHUMAN; ONCOGENE; PLZF GENE; PML GENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RARA GENE; REGULATORY MECHANISM; RNA INTERFERENCE; STEADY STATE; UBIQUITINATION; UPREGULATION; USP37 GENE;

ANIMALS; ARSENICALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; ENDOPEPTIDASES; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; ONCOGENE PROTEINS, FUSION; OXIDES; PROTEIN STABILITY; TRANSLOCATION, GENETIC;

EID: 84886799764     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.537     Document Type: Article

References (32)

1. Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: Implications for the clinical management of the disease. Blood Rev 2003; 17: 71-97
2. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-3215
3. Guibal FC, Alberich-Jorda M, Hirai H, Ebralidze A, Levantini E, Di Ruscio A et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 2009; 114: 5415-5425
4. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008; 14: 1333-1342
5. Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de The H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res 2009; 15: 6321-6326
6. Wang ZY, Chen Z. Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 2008; 111: 2505-2515
7. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L et al. Arsenic degrades PML or PML-RARalpha through a SUMO-Triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008; 10: 547-555
8. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010; 328: 240-243
9. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002; 82: 373-428
10. Ventii KH, Wilkinson KD. Protein partners of deubiquitinating enzymes. Biochem J 2008; 414: 161-175
11. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009; 78: 399-434
12. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123: 773-786
13. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009; 138: 389-403
14. Lin RJ, Sternsdorf T, Tini M, Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001; 20: 7204-7215
15. Duprez E, Wagner K, Koch H, Tenen DG. C/EBPbeta: A major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J 2003; 22: 5806-5816
16. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997; 16: 4226-4237
17. Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 2004; 13: 879-886
18. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463: 103-107
19. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 2007; 9: 765-774
20. Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009; 8: 2286-2295
21. Lee BH, Lee MJ, Park S, Oh DC, Elsasser S, Chen PC et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010; 467: 179-184
22. Huang X, Summers MK, Pham V, Lill JR, Liu J, Lee G et al. Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and promote S phase entry. Mol Cell 2011; 42: 511-523
23. Muller C, Yang R, Park DJ, Serve H, Berdel WE, Koeffler HP. The aberrant fusion proteins PML-RAR alpha and PLZF-RAR alpha contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia. Blood 2000; 96: 3894-3899
24. Yang R, Nakamaki T, Lubbert M, Said J, Sakashita A, Freyaldenhoven BS et al. Cyclin A1 expression in leukemia and normal hematopoietic cells. Blood 1999; 93: 2067-2074
25. Ji P, Agrawal S, Diederichs S, Baumer N, Becker A, Cauvet T et al. Cyclin A1, the alternative A-Type cyclin, contributes to G1/S cell cycle progression in somatic cells. Oncogene 2005; 24: 2739-2744
26. Doulatov S, Notta F, Rice KL, Howell L, Zelent A, Licht JD et al. PLZF is a regulator of homeostatic and cytokine-induced myeloid development. Genes Dev 2009; 23: 2076-2087
27. Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-Alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993; 12: 1161-1167
28. Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S et al. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Mol Cell Biol 1998; 18: 5533-5545
29. Buaas FW, Kirsh AL, Sharma M, McLean DJ, Morris JL, Griswold MD et al. Plzf is required in adult male germ cells for stem cell self-renewal. Nat Genet 2004; 36: 647-652
30. Costoya JA, Hobbs RM, Barna M, Cattoretti G, Manova K, Sukhwani M et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet 2004; 36: 653-659
31. Chang CC, Naik MT, Huang YS, Jeng JC, Liao PH, Kuo HY et al. Structural and functional roles of Daxx SIM phosphorylation in SUMO paralog-selective binding and apoptosis modulation. Mol Cell 2011; 42: 62-74
32. Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, Chao TT et al. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 2006; 24: 341-354